New drug combo aims to cut relapse in multiple myeloma transplant patients
NCT ID NCT07542418
First seen Apr 25, 2026 · Last updated Jun 10, 2026 · Updated 8 times
Summary
This study tests whether adding thiotepa to the standard chemotherapy (melphalan) before a stem cell transplant can lower the chance of cancer returning in people with multiple myeloma. It includes 204 adults aged 18-70 who did not achieve complete remission before transplant. Participants are randomly assigned to receive either the new combo or standard treatment, and are followed for one year to track relapse and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.